Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 175 participants.
Also called NCT03799627
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 175 participants
- Sponsor
- Registry
-
NCT03799627
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03799627. Randomized; no masking; primary purpose treatment. Start 2019-01-31 (actual); primary completion 2020-06-05 (actual). Results posted on 2022-09-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa
- Acronym
- FO2RWARD-2
- Condition
- Anemia
- Condition
- Dialysis-dependent Chronic Kidney Disease
- Intervention (Drug)
- Vadadustat
- Intervention (Drug)
- Epoetin Alfa
- Intervention (Drug)
- Vadadustat TIW
- Lead sponsor
- Akebia Therapeutics
Record details
- Record id
cardio:ct-nct03799627- Content hash
2155bf6ff27cad25e8c156f8fcffb946f8d24dfc746eed81b1ebd3623378ca99